Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
4.990
-0.140 (-2.73%)
At close: Jul 24, 2026, 4:00 PM EDT
4.980
-0.010 (-0.20%)
After-hours: Jul 24, 2026, 7:57 PM EDT
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Iovance Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $8.80. The average 1-year stock price forecast is 76.35% higher than the current stock price, while the lowest is $4.00 (-19.84%) and the highest is $14 (+180.56%).
Price Target: $8.80 (+76.35%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Jun 22, 2026.
Analyst Ratings
The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Maintains $10 | Buy | Maintains | $10 | +100.40% | Jun 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $9 | Buy | Reiterates | $9 | +80.36% | Jun 4, 2026 |
| Barclays | Barclays | Buy Maintains $11 | Buy | Maintains | $11 | +120.44% | Jun 2, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $14 | Buy | Reiterates | $14 | +180.56% | May 8, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $5 | Buy | Maintains | $5 | +0.20% | May 7, 2026 |
Financial Forecast
Revenue This Year
362.10M
from 263.50M
Increased by 37.42%
Revenue Next Year
496.28M
from 362.10M
Increased by 37.05%
EPS This Year
-0.56
from -1.09
EPS Next Year
-0.32
from -0.56
EPS and Forward PE are based on non-GAAP adjusted numbers.